NYSEAMERICAN:PTNPalatin Technologies Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Palatin Technologies, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $0.42 0.00 (0.00 %) (As of 04/3/2020 04:00 PM ET) Add Compare Share Today's Range$0.39Now: $0.42▼$0.4350-Day Range$0.87MA: $0.93▼$1.0652-Week Range$0.36Now: $0.42▼$1.78Volume772,435 shsAverage Volume1.54 million shsMarket Capitalization$95.91 millionP/E RatioN/ADividend YieldN/ABetaN/A ProfileAnalyst RatingsAdvanced ChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsSocial Media Palatin Technologies, Inc., a biopharmaceutical company, develops targeted, receptor-specific therapeutics for the treatment of various diseases in the United States. The company's principal product is Vyleesi, an on demand subcutaneous injectable product that has completed Phase III clinical studies for the treatment of premenopausal women with acquired, generalized hypoactive sexual desire disorder. Its drug development programs also include melanocortin receptor system program, such as PL-8177, a selective melanocortin receptor 1 agonist peptide for inflammatory bowel diseases; and PL-8331, a preclinical development candidate for treating ocular inflammation, as well as melanocortin receptor 4 peptides and orally-active small molecules to treat genetic metabolic and obesity disorders. In addition, the company develops natriuretic peptide receptor systems comprising PL3994, a natriuretic peptide receptor-A agonist, which has completed Phase I clinical study for the treatment of cardiovascular indications; and PL-5028, a dual natriuretic peptide receptor A and C agonist that is in preclinical development for cardiovascular diseases, such as reducing cardiac hypertrophy and fibrosis. Palatin Technologies, Inc. was founded in 1986 and is based in Cranbury, New Jersey.Read More Beat the Market (BTM) Rank™ 3.5 Analyst's Opinion Consensus RatingPalatin Technologies has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $3.67, Palatin Technologies has a potential upside of 776.4% from its current price of $0.42.Amount of Analyst CoveragePalatin Technologies has only been the subject of 1 research reports in the past 90 days. Previous Next 3.0 Community Rank Outperform VotesPalatin Technologies has received 420 “outperform” votes. (Add your “outperform” vote.)Underperform VotesPalatin Technologies has received 291 “underperform” votes. (Add your “underperform” vote.)Community SentimentPalatin Technologies has received 59.07% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Palatin Technologies and other stocks. Vote “Outperform” if you believe PTN will outperform the S&P 500 over the long term. Vote “Underperform” if you believe PTN will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldPalatin Technologies does not currently pay a dividend.Dividend GrowthPalatin Technologies does not have a long track record of dividend growth. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Palatin Technologies insiders have not sold or bought any company stock. Previous Next 0.0 Earnings and Valuation Previous Next Analyst Opinion: 3.5Community Rank: 3.0Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.30 out of 5 stars Industry, Sector and Symbol Stock Exchange NYSEAMERICAN Industry Diagnostics & Research Sub-IndustryN/A SectorMedical Current SymbolNYSEAMERICAN:PTN Previous SymbolNYSE:PTN CUSIPN/A CIK911216 Webhttp://www.palatin.com/ Phone+1-609-4952200Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/APrice-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AProfitability EPS (Most Recent Fiscal Year)N/A Net IncomeN/A Net MarginsN/A Return on EquityN/A Return on AssetsN/AMiscellaneous Employees19 Outstanding Shares229,241,000Market Cap$95.91 million Next Earnings Date5/14/2020 (Estimated) OptionableNot Optionable Receive PTN News and Ratings via Email Sign-up to receive the latest news and ratings for PTN and its competitors with MarketBeat's FREE daily newsletter. AMEX:PTN Rates by TradingView Palatin Technologies (NYSEAMERICAN:PTN) Frequently Asked Questions Do Wall Street analysts recommend investors buy shares of Palatin Technologies? 3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Palatin Technologies in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Palatin Technologies. When is Palatin Technologies' next earnings date? Palatin Technologies is scheduled to release its next quarterly earnings announcement on Thursday, May 14th 2020. View our earnings forecast for Palatin Technologies. How were Palatin Technologies' earnings last quarter? Palatin Technologies, Inc. (NYSEAMERICAN:PTN) issued its quarterly earnings results on Tuesday, February, 11th. The biopharmaceutical company reported ($0.02) EPS for the quarter, missing the consensus estimate of ($0.01) by $0.01. The biopharmaceutical company had revenue of $0.02 million for the quarter, compared to the consensus estimate of $4.48 million. During the same quarter last year, the firm earned ($0.02) EPS. View Palatin Technologies' earnings history. What price target have analysts set for PTN? 3 Wall Street analysts have issued 12-month price targets for Palatin Technologies' shares. Their forecasts range from $2.00 to $6.00. On average, they anticipate Palatin Technologies' stock price to reach $3.67 in the next twelve months. This suggests a possible upside of 776.4% from the stock's current price. View analysts' price targets for Palatin Technologies. Has Palatin Technologies been receiving favorable news coverage? News coverage about PTN stock has trended very negative this week, according to InfoTrie. The research group ranks the sentiment of media coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. Palatin Technologies earned a media sentiment score of -3.3 on InfoTrie's scale. They also assigned press coverage about the biopharmaceutical company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an effect on the stock's share price in the near future. View the latest news aboutPalatin Technologies. Who are some of Palatin Technologies' key competitors? Some companies that are related to Palatin Technologies include Senseonics (SENS), Volpara Health Tech (VHT), Profound Medical (PRN), Exagen (XGN), Akumin (AKU), Renalytix Ai (RENX), Yourgene Health (YGEN), Oncosil Medical (OSL), MaxCyte (MXCT), BARD1 Life Sciences (BD1), Lexagene (LXG), Oncimmune (ONC), SQI Diagnostics (SQD), Sernova (SVA) and GeneNews (GEN). What other stocks do shareholders of Palatin Technologies own? Based on aggregate information from My MarketBeat watchlists, some companies that other Palatin Technologies investors own include 22nd Century Group (XXII), Heat Biologics (HTBX), Alliqua Biomedical (ALQA), AVEO Pharmaceuticals (AVEO), Progenics Pharmaceuticals (PGNX), ImmunoGen (IMGN), AcelRx Pharmaceuticals (ACRX), Catalyst Pharmaceuticals (CPRX), Novavax (NVAX) and Actinium Pharmaceuticals (ATNM). Who are Palatin Technologies' key executives? Palatin Technologies' management team includes the following people: Dr. John K. A. Prendergast, Co-Founder & Non-Exec. Chairman (Age 65)Dr. Carl Spana, Co-Founder, Pres, CEO & Director (Age 57)Mr. Stephen T. Wills CPA, CPA, MST, CFO, COO, Exec. VP, Treasurer & Sec. (Age 62)Burns McClellan, VP of Investor Relations What is Palatin Technologies' stock symbol? Palatin Technologies trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "PTN." How do I buy shares of Palatin Technologies? Shares of PTN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Palatin Technologies' stock price today? One share of PTN stock can currently be purchased for approximately $0.42. How big of a company is Palatin Technologies? Palatin Technologies has a market capitalization of $95.91 million. Palatin Technologies employs 19 workers across the globe. View additional information about Palatin Technologies. What is Palatin Technologies' official website? The official website for Palatin Technologies is http://www.palatin.com/. How can I contact Palatin Technologies? Palatin Technologies' mailing address is 4B Cedarbrook Dr, CRANBURY, NJ 08512-3641, United States. The biopharmaceutical company can be reached via phone at +1-609-4952200. This page was last updated on 4/4/2020 by MarketBeat.com StaffFeatured Article: Moving Average - How it Helps Investors in Stock Selection
